Literature DB >> 23532530

Novel oral anti-obesity agents: new perspectives with lorcaserin?

Baptist Gallwitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23532530     DOI： 10.1007/s40265-013-0039-x

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  16 in total

1.  Multicenter, placebo-controlled trial of lorcaserin for weight management.

Authors:  Steven R Smith; Neil J Weissman; Christen M Anderson; Matilde Sanchez; Emil Chuang; Scott Stubbe; Harold Bays; William R Shanahan
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

3.  Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

Authors:  W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

Review 4.  Cardiovascular risk-benefit profile of sibutramine.

Authors:  A J Scheen
Journal:  Am J Cardiovasc Drugs       Date:  2010       Impact factor: 3.571

5.  The number of years lived with obesity and the risk of all-cause and cause-specific mortality.

Authors:  Asnawi Abdullah; Rory Wolfe; Johannes U Stoelwinder; Maximilian de Courten; Christopher Stevenson; Helen L Walls; Anna Peeters
Journal:  Int J Epidemiol       Date:  2011-02-27       Impact factor: 7.196

6.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Authors:  Meredith C Fidler; Matilde Sanchez; Brian Raether; Neil J Weissman; Steven R Smith; William R Shanahan; Christen M Anderson
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

7.  Phentermine and topiramate extended release (Qsymia™): first global approval.

Authors:  Fiona Cameron; Glenn Whiteside; Kate McKeage
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

Review 8.  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.

Authors:  David Bradley; Faidon Magkos; Samuel Klein
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

Review 9.  Weight loss surgery for mild to moderate obesity: a systematic review and economic evaluation.

Authors:  Joanna Picot; Jeremy Jones; Jill L Colquitt; Emma Loveman; Andrew J Clegg
Journal:  Obes Surg       Date:  2012-09       Impact factor: 4.129

10.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.

Authors:  A Astrup; R Carraro; N Finer; A Harper; M Kunesova; M E J Lean; L Niskanen; M F Rasmussen; A Rissanen; S Rössner; M J Savolainen; L Van Gaal
Journal:  Int J Obes (Lond)       Date:  2011-08-16       Impact factor: 5.095
View more
  3 in total

1.  Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?

Authors:  Andrew J Krentz; Marcus Hompesch
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

2.  Anti-Obesity Effect of Chitosan Oligosaccharide Capsules (COSCs) in Obese Rats by Ameliorating Leptin Resistance and Adipogenesis.

Authors:  Haitao Pan; Chuhan Fu; Lanlan Huang; Yao Jiang; Xiaoyi Deng; Jiao Guo; Zhengquan Su
Journal:  Mar Drugs       Date:  2018-06-05       Impact factor: 5.118

Review 3.  An overview on recent in vivo biological application of cerium oxide nanoparticles.

Authors:  Baskaran Stephen Inbaraj; Bing-Huei Chen
Journal:  Asian J Pharm Sci       Date:  2019-11-27       Impact factor: 6.598
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.